Health insurance stands as a pivotal facet of social wellbeing, with profound implications for the overarching landscape of economic development. The existing research, however, lacks consensus on the relationship between health insurance and economic performance and provides no evidence about the magnitude of the correlation. This lack of information seriously impedes the high-quality development of the healthcare system. Therefore, to scientifically elucidate the relationship between the two, this study involved a meta-analysis, analyzing 479 effect values derived from 34 independent research samples. The results reveal a strongly positive correlation between health insurance and economic performance [r = 0.429, 95% CI = (0.381, 0.475)]. Findings show that health insurance in developed countries more effectively fosters economic performance than in developing countries. Moreover, public health insurance exerts a stronger promoting effect on economic performance than commercial health insurance. The relationship between health insurance and economic performance is moderated by data type, research method, country of sample origin, literature type, journal impact factor, publication year, type of health insurance, and the research populations. Based on meta-analysis, this study not only scientifically responds to the controversy of the relationship between health insurance and economic performance, and the magnitude of a correlation, but also further reveals the inner conduction mechanism between the two. Our research findings are meaningful for policymakers to choose an appropriate healthcare strategy according to their unique attributes, propelling sustainable economic development.

Biogenetic resources are the foundation of biodiversity and are of great significance to the sustainability of human society. The effective promotion of biogenetic resource conservation depends on the scientific formulation and implementation of relevant policies, so the quantitative evaluation of biogenetic resource conservation policies can provide decision support for the next step of policy formulation. Based on text analysis, social network analysis, and the construction of the PMC index model, this study selected 132 policy samples issued by the Chinese government in the field of biogenetic resources, established an evaluation system for China’s biogenetic resources policies, which contains 10 first-level indicators and 55 s-level indicators, and drew the PMC curve diagram accordingly to quantitatively evaluate China’s biogenetic resources policies. The results show that China’s biogenetic resources policies are generally at a good level, which can meet the current practical needs of biogenetic resources conservation, but there are problems such as the lack of policy forecasts in the relevant policy texts, the lack of flexible planning in the short and medium term, the lack of co-operation among the policy issuers, and the insufficient guidance of innovation. Based on the results, this article puts forward suggestions for improving China’s biogenetic resource conservation policies.

The growing research interest in the relationship between health insurance and pharmaceutical innovation is driven by their significant impact on healthcare optimization and pharmaceutical development. The existing literature, however, lacks consensus on this relationship and provides no evidence of the magnitude of a correlation. In this context, this study employs meta-analysis to explore the extent to which health insurance affects pharmaceutical innovation. It analyzes 202 observations from 14 independent research samples, using the regression coefficient of health insurance on pharmaceutical innovation as the effect size. The results reveal that there is a strong positive correlation between health insurance and pharmaceutical innovation (r = 0.367, 95% CI = [0.294, 0.436]). Public health insurance exhibits a stronger promoting effect on pharmaceutical innovation than commercial health insurance. The relationship between health insurance and pharmaceutical innovation is moderated by the country of sample origin, data range, journal type, journal impact factor, type of health insurance, and research perspective. Our research findings further elucidate the relationship mechanism between health insurance and pharmaceutical innovation, providing a valuable reference for future explorations in pharmaceutical fields.